CD39 Recombinant Rabbit Monoclonal Antibody - BSA and Azide free [JA90-36] (HA750421)

UNIPROT #

P49961

PROTEIN NAME

CD39

SYNONYMS

ATPDase antibody;CD 39 antibody;CD39 antibody;CD39 antigen antibody;DKFZp686D194 antibody;DKFZp686I093 antibody;Ecto apyrase antibody;Ecto ATP diphosphohydrolase antibody;Ecto-apyrase antibody;Ecto-ATP diphosphohydrolase 1 antibody;Ecto-ATPase 1 antibody;Ecto-ATPDase 1 antibody;Ectonucleoside triphosphate diphosphohydrolase 1 antibody;ENTP1_HUMAN antibody;ENTPD 1 antibody;ENTPD1 antibody;FLJ40921 antibody;FLJ40959 antibody;Lymphoid cell activation antigen antibody;NTPDase 1 antibody;NTPDase1 antibody;SPG64 antibody

SEQUENCE SIMILARITIES

Belongs to the GDA1/CD39 NTPase family.

TISSUE SPECIFICITY

Expressed primarily on activated lymphoid cells. Also expressed in endothelial tissues. Isoform 1 and isoform 3 are present in both placenta and umbilical vein, whereas isoform 2 is present in placenta only.

POST-TRANSLATIONAL MODIFICATION

The N-terminus is blocked.; Palmitoylated in the N-terminal part.

SUBCELLULAR LOCATION

Membrane.

FUNCTION

CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENP1), is an integral membrane glycoprotein that acts as an extracellular nucleotide-hydrolyzing enzyme. CD39 inhibits ADP-induced platelet aggregation by hydrolyzing ADP to AMP and ultimately generating adenosine. Intracellular CD39 undergoes glycosylation at 6 N-glycosylation sites and translocates to the membrane in order to be an active enzyme. Alternative splicing gives rise to three CD39 isoforms, vascular, placenta I and placenta II. The placenta I isoform differs at the amino terminus whereas the placenta II isoform is missing amino acids 300-510 at the C-terminus. CD39 is expressed in vascular tissues including placenta, lung, skeletal muscle and kidney, as well as endothelium, smooth muscle, cardiac cells, lymphocytes (such as activated B cells) activated NK cells, macrophages, dendridic cells and platelets. CD39 may be used as an anti-thrombic agent for pre-treating patients at risk for coronary artery occlusion and thrombic stroke.